TRIPASS XR تري باس

 

SAC (see Seasonal allergic conjunctivitis (SAC))

Saccharides (see Carbohydrates)

Saccharomyces, 2161

SAD (see Social anxiety disorder (SAD))

Safe Practices for Parenteral Nutrition Formulations, 792

Salicylism, 68–70

Salmonella infection, 1453–1457

extraintestinal, 1454–1455

invasive nontyphoidal, 1455–1457

nontyphoidal, 1454

typhoidal, 1455–1457

Salmonella typhimurium, 495

SAPASI (see The Self-Administered Psoriasis Area and Severity Index (SAPASI))

Sarcoptes scabiei var. hominis, 1712

SARS (see Severe acute respiratory distress syndrome (SARS))

SARS coronavirus (SARS-CoV), 1660

SAS (see Sedation-Agitation Scale (SAS))

SBP (see Spontaneous bacterial peritonitis (SBP); Systolic blood pressure (SBP))

SBS (see Short bowel syndrome (SBS))

Scabies, 1712

Scarlatiniform eruptions, 823

SCC (see Squamous cell carcinoma (SCC))

SCCM (see Society of Critical Care Medicine (SCCM))

SCD (see Sudden cardiac death (SCD))

Schizophrenia, 1790

antidepressants, 1809–1810

antipsychotic selection, 1790–1806

anxiety in, 1784

assessment, 1786–1787

clinical presentation of, 1782–1785

course of, 1784–1785

depression in, 1784

diagnosis and differential diagnosis, 1782–1783, 1783t

DSM-5 criteria for, 1782t

early-onset, 1811–1812

economic burden, 1781

epidemiology, 1781

genetic and environmental risk factors, 1781

historical concept, 1782

inadequate response, 1806–1807

nonantipsychotic agents, 1809–1810

pathophysiology, 1781–1782

pharmacotherapy interventions, 1787–1790

prognosis, 1784–1785

psychosis, 1782, 1811–1812

serum concentration monitor, 1809

symptoms, 1783–1784

treatment, 1810

CBT for, 1785

goals of, 1785

group therapy, 1786

nonpharmacologic interventions, 1785–1786

pharmacologic interventions, 1785

psychosocial, 1785

SCIP (see Surgical Care Improvement Project (SCIP))

SCIT (see Subcutaneous immunotherapy (SCIT))

SCLC (see Small-cell lung cancer (SCLC))

SCr (see Serum creatinine (SCr))

Screener and Opioid Assessment of Patients with Pain-Revised (SOAPP-R), 1184, 1196

SDAI (see Simplified Disease Activity Index (SDAI))

Seasonal allergic conjunctivitis (SAC), 438

Seasonal asthma, 395

Secondary headache, 1234–1235

acute, 1234

subacute, 1234–1235

Secondary hypertension, 136–137t

Secondary peritonitis, 1477–1480

diagnosis of, 1477–1478

etiology of, 1477–1478

pathogenesis of, 1477

Secondary prophylaxis, 550–551

Second Assessment of Safety and Efficacy of a New Thrombolytic (ASSENT-2), 251

Second-degree atrioventricular block, 321f

Secondhand smoke exposure, 1905

Second International Study of Infarct Survival (ISIS-2), 251

Sedation-Agitation Scale (SAS), 1212

Sedative-hypnotics, 1881–1882

Seizures, 78, 971, 1273–1300, 2190–2191

classification of, 1274–1275, 1274t

definition of, 1274

diagnosis of, 1275–1276

in elderly, 1289–1290

neonatal, 2190–2193

from salicylate toxicity, 70

treatment of, 1276–1280

The Self-Administered Psoriasis Area and Severity Index (SAPASI), 834

Self-monitored blood glucose (SMBG), 1082, 1095–1096t

concentrations, interpreting, 1093t

factors affecting, 1096t

testing, 1092t

for type 1 diabetes, 1095–1096

for type 2 diabetes, 1133

Semisynthetic dressings, 862–863

Sepsis, 1320

ARDS and, 1322

cellular changes in, 1321

CNS changes in, 1322

definition of, 2204t

DIC and, 1322

hematologic changes in, 1322

hemodynamic changes in, 1320–1321

neurologic changes in, 1322

pathogenesis of, 1321f

respiratory changes in, 1321–1322

syndrome, 366

clinical features, 367–368

task force definitions, 366t

Septic arthritis, 1541–1542

Septic shock

characteristics of, 367

clinical and hemodynamic features, 368

definition of, 2204t

distributive shock, 366–368

therapeutic approach, 368–373

Sequential Organ Failure Assessment (SOFA) score, 366, 367t